J M Jacobson
Affiliation: Mount Sinai School of Medicine
- Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcersJ M Jacobson
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
J Infect Dis 183:343-346. 2001..Thalidomide in lower intermittent doses is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons...
- Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials GroupJ M Jacobson
Mount Sinai Medical Center, New York, NY 10029, USA
J Infect Dis 180:61-7. 1999..Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV...
- Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson
Mount Sinai Medical Center, New York, NY 10029 6574, USA
J Infect Dis 182:326-9. 2000..No patient developed antibodies to PRO 542. Preliminary evidence of antiviral activity was observed as reductions in both plasma HIV RNA and plasma viremia. Sustained antiviral effects may be achieved with repeat dosing with PRO 542...
- Thalidomide: a remarkable comebackJ M Jacobson
Department of Medicine, Mount Sinai Medical School, Box 1009 1 Gustave Levy Place, New York, NY 10029, USA
Expert Opin Pharmacother 1:849-63. 2000..Adverse effects include teratogenicity, peripheral neuropathy and sedation. In the US, thalidomide can be prescribed only through a restricted drug distribution program...